Scottish Medicines Consortium
Providing advice about the status of all newly licensed medicines
www.scottishmedicines.org.uk
Delta House 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Professor Jonathan G Fox

Product Update:

emtricitabine/tenofovir alafenamide 200mg/25mg, 200mg/10mg film-coated tablets (Descovy®) SMC No. (1169/16)
Gilead Sciences Ltd

08 July 2016

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) and on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

emtricitabine/tenofovir alafenamide (Descovy®) is accepted for use within NHS Scotland.

Indication under review: in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.

For adult patients in whom emtricitabine/tenofovir is an appropriate combination, Descovy® (emtricitabine/tenofovir alafenamide) offers an alternative to Truvada® (emtricitabine/tenofovir disoproxil) at no additional cost, and may also be used in patients from 12 years of age.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 15 June 2016.

Chairman
Scottish Medicines Consortium

Published 08 August 2016